Three Stocks That May Be Trading Below Estimated Value In May 2026

Alkami Technology is trading at US$17.59, significantly below its estimated future cash flow value of US$30.58, suggesting it is undervalued based on discounted cash flow analysis. The company expects to become profitable within three years, with earnings projected to grow substantially each year. However, recent insider selling and slower revenue growth compared to some benchmarks may warrant caution despite analyst consensus predicting a 23% rise in stock price.

Omada Health trades at US$17.82, well below its estimated future cash flow value of US$28.24, highlighting potential undervaluation. The company expects profitability within three years, with earnings growth forecast at 95.77% annually, surpassing market averages. Recent developments include a partnership with Eli Lilly’s Employer Connect program and strong Q1 2026 financials showing revenue growth and reduced net losses year-over-year, though return on equity remains low at a projected 7.1%.